Findings

What do systematic reviews say?

4,710 questions · 14,842 findings · 1,394 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2,880 · 19.4%GRADE not reported 1,413 · 9.5%Very low 3,103 · 20.9%Low 3,870 · 26.1%Moderate 2,663 · 17.9%High 913 · 6.2%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Heliox vs placebo or no treatment

Length of hospital stay · children with croup

The review found no eligible studies for this question.

1 finding from 1 review

Heliox for croup in children 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Heliox vs placebo or no treatment

Proportion of children intubated · children with croup

The review found no eligible studies for this question.

1 finding from 1 review

Heliox for croup in children 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Heliox vs placebo or no treatment

Duration of intubation · children with croup

The review found no eligible studies for this question.

1 finding from 1 review

Heliox for croup in children 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Heliox vs placebo or no treatment

Proportion of children re‐presenting for medical care for ongoing croup symptoms (return to care) · children with croup

Heliox showed no clear difference in proportion of children re‐presenting for medical care for ongoing… compared with placebo or no treatment (low certainty).

1 finding from 1 review

Heliox for croup in children 2021 · Cochrane Headline outcomes only
OR 0.95 [0.12, 7.41]
1 study · 47 participants
Low

Heliox vs placebo or no treatment

Adverse events · children with croup

The review found no eligible studies for this question.

1 finding from 1 review

Heliox for croup in children 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oral methotrexate vs placebo

Primary outcome: complete clinical response (malar/discoid rash) · patients with cutaneous disease in systemic lupus erythematosus

Oral methotrexate may leads to higher primary outcome: complete clinical response (malar/discoid rash) compared with placebo (low certainty).

1 finding from 1 review

Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes only
RR 3.57 [1.63, 7.84]
1 study · 41 participants
Low

Oral hydroxychloroquine vs placebo

Secondary outcome: clinical flare · patients with cutaneous disease in systemic lupus erythematosus

Oral hydroxychloroquine probably leads to lower secondary outcome: clinical flare compared with placebo (moderate certainty).

1 finding from 1 review

Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes only
RR 0.49 [0.28, 0.89]
1 study · 47 participants
Moderate

Oral hydroxychloroquine vs placebo

Secondary outcome: CLASI · patients with cutaneous disease in systemic lupus erythematosus

1 finding from 1 review

Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Oral hydroxychloroquine vs placebo

Secondary outcome: Dermatology Quality of Life measure · patients with cutaneous disease in systemic lupus erythematosus

1 finding from 1 review

Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Oral hydroxychloroquine vs placebo

Adverse events: severe · patients with cutaneous disease in systemic lupus erythematosus

Oral hydroxychloroquine showed no clear difference in adverse events: severe compared with placebo (moderate certainty).

1 finding from 1 review

Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes only
RR 3.9 [0.19, 78.46]
1 study · 71 participants
Moderate

Oral hydroxychloroquine vs placebo

Minor adverse events · patients with cutaneous disease in systemic lupus erythematosus

Oral hydroxychloroquine showed no clear difference in adverse events: minor compared with placebo (moderate certainty).

1 finding from 1 review

Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes only
RR 1.32 [0.24, 7.19]
1 study · 47 participants
Moderate

Oral dehydroepiandrosterone vs placebo

Complete response · patients with cutaneous disease in systemic lupus erythematosus

Oral dehydroepiandrosterone showed no clear difference in primary outcome: complete clinical response compared with placebo (moderate certainty).

1 finding from 1 review

Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes only
RR 1.11 [1, 1.22]
1 study · 381 participants
Moderate

Oral dehydroepiandrosterone vs placebo

Primary outcome: partial clinical response · patients with cutaneous disease in systemic lupus erythematosus

1 finding from 1 review

Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Oral dehydroepiandrosterone vs placebo

Secondary outcome: clinical flare · patients with cutaneous disease in systemic lupus erythematosus

1 finding from 1 review

Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Oral dehydroepiandrosterone vs placebo

Secondary outcome: CLASI · patients with cutaneous disease in systemic lupus erythematosus

1 finding from 1 review

Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Oral dehydroepiandrosterone vs placebo

Secondary outcome: Dermatology Quality of Life measure · patients with cutaneous disease in systemic lupus erythematosus

1 finding from 1 review

Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Oral methotrexate vs placebo

Primary outcome: partial clinical response · patients with cutaneous disease in systemic lupus erythematosus

1 finding from 1 review

Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Oral dehydroepiandrosterone vs placebo

Adverse events: severe · patients with cutaneous disease in systemic lupus erythematosus

Oral dehydroepiandrosterone showed no clear difference in adverse events: severe compared with placebo (moderate certainty).

1 finding from 1 review

Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes only
RR 0.09 [0.01, 1.66]
1 study · 381 participants
Moderate

Oral dehydroepiandrosterone vs placebo

Minor adverse events · patients with cutaneous disease in systemic lupus erythematosus

Oral dehydroepiandrosterone probably leads to higher adverse events: minor compared with placebo (moderate certainty).

1 finding from 1 review

Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes only
RR 10.5 [3.26, 33.75]
1 study · 381 participants
Moderate

Oral chloroquine vs placebo

Complete response · patients with cutaneous disease in systemic lupus erythematosus

Oral chloroquine showed no clear difference in primary outcome: complete clinical response compared with placebo (low certainty).

1 finding from 1 review

Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes only
RR 1.57 [0.95, 2.61]
1 study · 24 participants
Low